Nivolumab

The FDA approved nivolumab in combination with cabozantinib as first-line treatment of patients with advanced renal cell carcinoma, according to a manufacturer-issued press release.

The gut microbiome potentially could serve as a biomarker to predict the efficacy of nivolumab among patients with advanced gastric cancer, according to results of the DELIVER trial presented at Gastrointestinal Cancers Symposium.

The FDA granted priority review to nivolumab for two gastrointestinal cancer indications, according to the agent’s manufacturer.

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

The University of Texas MD Anderson Cancer Center recently named Welela Tereffe, MD, as its chief medical executive. It was the top story in hematology/oncology last week.

Bristol Myers Squibb withdrew nivolumab from the U.S. market for the treatment of patients with small cell lung cancer that progressed after platinum-based chemotherapy and at least one other therapy, according to a press release.

Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation showed promise in patients with high-risk Hodgkin lymphoma, according to a presentation at the ASH Annual Meeting and Exposition.

The addition of stereotactic body radiation therapy to nivolumab did not improve outcomes among a cohort of patients with metastatic head and neck squamous cell carcinoma, according to a study published in Journal of Clinical Oncology.

A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and nivolumab, according to results of an analysis presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.

Continued nivolumab treatment after 1 year appeared effective and safe for certain patients with advanced non-small cell lung cancer, according to an exploratory analysis of the CheckMate 153 study published in Journal of Clinical Oncology.